Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480602 | 0.92 | TRPV4 (0.32) | PTGDRPTGDR2 | |
| SCHEMBL12979721 | 0.90 | AR (0.33) | ARPLA2G7CCR1CCR2CCR5 | |
| SCHEMBL3480747 | 0.88 | PLA2G7 (0.31) | ARPLA2G7RXRARXRBRXRG | |
| SCHEMBL3996581 | 0.88 | PLA2G7 (0.35) | ARPLA2G7CCR1CCR2CCR5 | |
| SCHEMBL3480426 | 0.86 | PTGDR (0.32) | PTGDRPTGDR2 | |
| SCHEMBL13021440 | 0.86 | PLA2G7 (0.34) | ARPLA2G7CCR1CCR2CCR5 | |
| SCHEMBL3480818 | 0.85 | AR (0.32) | ARRXRARXRBRXRG | |
| Trifluoroacetic Acid SCHEMBL3948690 | 0.84 | PLA2G7 (0.34) | ARPLA2G7 | |
| SCHEMBL13022858 | 0.84 | AR (0.35) | ARPLA2G7 | |
| SCHEMBL3480088 | 0.84 | PTGDR2 (0.35) | PTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | claimed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | AR 4623/4885PLA2G7 289/4885RXRA 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.